Theravance Biopharma (TBPH) stock price is $17.03, unchanged on the day, as of Sep 25, 2026. It has a market cap of $883.70Mn and a P/E ratio of 16.35, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap883.70 Mn
P/E16.35
P/S8.47
Revenue Growth (1y) (Qtr)-20.86
Add ratio to table…
About
Theravance Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines targeting respiratory and other chronic diseases. The company’s primary commercial product, YUPELRI, is an FDA-approved once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease. Theravance Biopharma operates in a highly regulated industry, leveraging partnerships and royalty arrangements…
Theravance Biopharma, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines targeting respiratory and other chronic diseases. The company’s primary commercial product, YUPELRI, is an FDA-approved once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease. Theravance Biopharma operates in a highly regulated industry, leveraging partnerships and royalty arrangements to drive revenue while managing a lean operational structure centered on outsourced manufacturing and research activities.
The company generates revenue through product sales, profit-sharing agreements, royalties, and milestone payments. Its flagship product, YUPELRI, contributes directly to revenue via a profit-sharing arrangement with commercial partner Viatris Inc., where Theravance Biopharma retains a 35% share of net profits. Additionally, the company earns royalties from global net sales of TRELEGY, a triple-therapy inhaler developed by GSK, though it sold its remaining royalty interest in 2025 while retaining rights to potential milestone payments. Other revenue streams include upfront payments, regulatory milestones, and licensing fees tied to developmental programs and partnerships.
The company operates through the following segments.
Commercial Products. This segment centers on YUPELRI, a once-daily nebulized therapy for COPD patients who require or prefer nebulized delivery. The product is co-promoted in the U. S. under a profit-sharing agreement with Viatris, while international rights (excluding China) are licensed to Viatris in exchange for tiered royalties. Theravance Biopharma retains rights to alternative dosage forms, such as metered-dose and dry powder inhalers, for future development.
Royalty and Milestone Interests. The company holds economic interests in external products, primarily TRELEGY, a once-daily triple-therapy inhaler for COPD and asthma marketed by GSK. Though Theravance Biopharma sold its remaining royalty interest in 2025, it retains rights to receive up to $150 million in milestone payments tied to future sales thresholds. Additional milestone payments are linked to regulatory and commercial achievements in China and other international markets.
Research and Development. Historically, this segment focused on advancing internal pipeline candidates, including ampreloxetine, a norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension in multiple system atrophy patients. Following the failure of its Phase 3 CYPRESS study in 2026, the company decided to wind down the ampreloxetine program and is restructuring to eliminate most R&D activities, reallocating resources toward commercial operations.
Theravance Biopharma occupies a niche position within the respiratory therapeutics market, competing in a landscape dominated by larger pharmaceutical companies with broader portfolios and commercial infrastructures. Its competitive advantage lies in YUPELRI’s unique once-daily nebulized formulation, addressing an underserved segment of COPD patients who cannot or prefer not to use handheld inhalers. The product benefits from strong intellectual property protection, with Orange Book-listed patents extending into the late 2030s, and a settled patent litigation strategy that delays generic competition until 2039. However, the company faces competition from alternative therapies, including IL-4/IL-13 and IL-5 monoclonal antibodies, as well as emerging nebulized treatments like Merck’s Ohtuvayre. Its reliance on partnerships, particularly with Viatris and GSK, exposes it to execution risks tied to third-party commercialization efforts.
The company’s customer base primarily consists of COPD patients in the U. S. and international markets, with prescriptions driven by pulmonologists, primary care physicians, and respiratory therapists. YUPELRI is distributed through pharmacies and healthcare providers specializing in nebulized therapies, while TRELEGY’s customer base includes both COPD and asthma patients globally. Specific customer names are not disclosed, but the company’s revenue is derived from partnerships with pharmaceutical distributors, insurers, and government payors, including Medicare and Medicaid in the U. S.
Sector:HealthcareSector rationaleTheravance Biopharma is a biopharmaceutical company that develops and commercializes medicines for respiratory diseases, specifically its FDA-approved product YUPELRI for COPD. Its revenue is derived from product sales, profit-sharing, and royalties from pharmaceutical partners like Viatris and GSK, which fits squarely within the Pharmaceuticals and Biotechnology industries of the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryTheravance Biopharma is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting respiratory diseases. Its revenue is driven by biologic-related product sales, profit-sharing agreements for YUPELRI, and milestone payments from partnerships with GSK and Viatris.Classified using BQ-MICSCIK: 0001583107
Bull & bear
Investment Thesis
▲ Bull case
Theravance Biopharma has demonstrated the durability of its core commercial asset YUPELRI through consistent year-over-year sales growth and record profitability despite the setback from the failed CYPRESS study, with YUPELRI net sales reaching $266.6 million in 2025 (up 12% year-over-year) and generating a new all-time high for brand-level profitability, indicating that the product has achieved sustainable commercial traction in the COPD market through expanding community and hospital adoption, improved net pricing, and the recent resolution of generic litigation, which together provide a foundation for predictable cash flow generation independent of pipeline outcomes.
The organizational restructuring initiated after the CYPRESS failure is a strategic inflection point that will reduce operating expenses by approximately 60% relative to 2025 actuals of $111.1 million, yielding full run-rate cost savings of approximately $70 million by Q3 2026, which when combined with continued YUPELRI sales is projected to generate $60 to $70 million of annualized cash flow starting in Q3 2026, transforming the company from a cash-burning R&D entity into a self-sustaining cash generator with meaningful free cash flow conversion that the market is overlooking amid near-term EPS volatility.
The Strategic Review Committee's accelerated evaluation of value-maximizing alternatives, including a potential sale of the company, represents a material catalyst that is not fully priced in, as the company holds a strong set of assets including approximately $400 million of expected cash at the end of Q1 2026, a 35% interest in YUPELRI generating durable cash flow, Irish tax attributes, and the potential $100 million TRELEGY milestone payment contingent on GSK's TRELEGY global net sales, creating multiple pathways to unlock shareholder value beyond the current public market valuation that reflects only the downside scenario of the ampreloxetine failure.
YUPELRI's long-term commercial viability is underpinned by U.S. patent protection through 2039 and its unique positioning as the first and only once-daily nebulized LAMA approved for COPD maintenance treatment, which provides a defensible moat against generic competition and supports durable market share gains in both community and hospital settings, with Viatris reporting strong uptake and the company benefiting from a 35% profit share under the co-promotion agreement, ensuring that any growth in YUPELRI sales directly translates to higher cash flow for Theravance without incremental commercial investment.
The company's balance sheet strength, with $394.7 million in cash and short-term marketable securities as of March 31, 2026 (up from $315.4 million at December 31, 2025) and zero debt, provides a substantial financial runway to execute strategic alternatives, withstand near-term restructuring costs of $5 to $7 million in one-time cash severance, and capitalize on value-accretive opportunities without dilution or distressed financing, a factor that is underappreciated given the market's focus on the failed pipeline program rather than the fortress-like financial position supporting the commercial franchise.
Theravance Biopharma has demonstrated the durability of its core commercial asset YUPELRI through consistent year-over-year sales growth and record profitability despite the setback from the failed CYPRESS study, with YUPELRI net sales reaching $266.6 million in 2025 (up 12% year-over-year) and generating a new all-time high for brand-level profitability, indicating that the product has achieved sustainable commercial traction in the COPD market through expanding community and hospital adoption, improved net pricing, and the recent resolution of generic litigation, which together provide a foundation for predictable cash flow generation independent of pipeline outcomes.
The organizational restructuring initiated after the CYPRESS failure is a strategic inflection point that will reduce operating expenses by approximately 60% relative to 2025 actuals of $111.1 million, yielding full run-rate cost savings of approximately $70 million by Q3 2026, which when combined with continued YUPELRI sales is projected to generate $60 to $70 million of annualized cash flow starting in Q3 2026, transforming the company from a cash-burning R&D entity into a self-sustaining cash generator with meaningful free cash flow conversion that the market is overlooking amid near-term EPS volatility.
The Strategic Review Committee's accelerated evaluation of value-maximizing alternatives, including a potential sale of the company, represents a material catalyst that is not fully priced in, as the company holds a strong set of assets including approximately $400 million of expected cash at the end of Q1 2026, a 35% interest in YUPELRI generating durable cash flow, Irish tax attributes, and the potential $100 million TRELEGY milestone payment contingent on GSK's TRELEGY global net sales, creating multiple pathways to unlock shareholder value beyond the current public market valuation that reflects only the downside scenario of the ampreloxetine failure.
YUPELRI's long-term commercial viability is underpinned by U.S. patent protection through 2039 and its unique positioning as the first and only once-daily nebulized LAMA approved for COPD maintenance treatment, which provides a defensible moat against generic competition and supports durable market share gains in both community and hospital settings, with Viatris reporting strong uptake and the company benefiting from a 35% profit share under the co-promotion agreement, ensuring that any growth in YUPELRI sales directly translates to higher cash flow for Theravance without incremental commercial investment.
The company's balance sheet strength, with $394.7 million in cash and short-term marketable securities as of March 31, 2026 (up from $315.4 million at December 31, 2025) and zero debt, provides a substantial financial runway to execute strategic alternatives, withstand near-term restructuring costs of $5 to $7 million in one-time cash severance, and capitalize on value-accretive opportunities without dilution or distressed financing, a factor that is underappreciated given the market's focus on the failed pipeline program rather than the fortress-like financial position supporting the commercial franchise.
Theravance Biopharma's overreliance on YUPELRI as the sole commercial asset creates significant concentration risk, as the product's growth is dependent on continued uptake in a competitive COPD market where established therapies like TRELEGY (which generated $3.9 billion in full-year 2025 net sales for GSK) dominate prescribing patterns, and any slowdown in YUPELRI's 12% year-over-year growth trajectory could quickly erode the projected $60 to $70 million annualized cash flow, especially given that the company has wound down its R&D function and lacks a diversified pipeline to offset commercial underperformance.
The $100 million TRELEGY milestone payment, frequently cited as a near-term catalyst, is contingent on GSK achieving specific global net sales thresholds for TRELEGY, which grew only 2% year-over-year in Q1 2026 to $873 million, suggesting that the milestone may be delayed or even unattainable if TRELEGY sales growth continues to decelerate, and the company's forward-looking cash flow projections explicitly exclude this potential income, indicating that management itself views it as uncertain rather than a guaranteed near-term driver.
Despite the organizational restructuring reducing headcount by approximately 50% and targeting $70 million in annual cost savings, the company still reported a GAAP net loss of $4.9 million in Q1 2026 and non-GAAP net income of only $0.6 million, revealing that even after significant cost cuts, profitability remains fragile and highly sensitive to fluctuations in YUPELRI sales or unexpected expenses, with the path to sustained GAAP profitability unclear given the permanent loss of R&D capabilities and the structural shift to a pure-play commercial entity.
The ongoing Strategic Review Committee process, while highlighting potential value-maximizing alternatives including a sale, carries substantial execution risk and uncertainty, as there can be no assurance that any transaction will occur, and the company's history of failed pipeline investments (ampspreloxetine) combined with its limited commercial scale raises doubts about its attractiveness as a standalone acquisition target, particularly when compared to larger pharmaceutical companies with diversified respiratory portfolios that could develop internal YUPELRI equivalents or negotiate better terms with Viatris.
YUPELRI's long-term prospects face headwinds from evolving COPD treatment guidelines that increasingly favor triple therapy regimens like TRELEGY over monotherapy LAMAs, potential pressure from future generic entrants despite patent protection through 2039 (which may be challenged via patent evergreening or formulation workarounds), and the inherent limitations of nebulized delivery systems in a market shifting toward inhaler-based therapies, all of which could constrain YUPELRI's market share growth and undermine the durability of its cash flow stream that the bullish thesis depends upon.
Theravance Biopharma's overreliance on YUPELRI as the sole commercial asset creates significant concentration risk, as the product's growth is dependent on continued uptake in a competitive COPD market where established therapies like TRELEGY (which generated $3.9 billion in full-year 2025 net sales for GSK) dominate prescribing patterns, and any slowdown in YUPELRI's 12% year-over-year growth trajectory could quickly erode the projected $60 to $70 million annualized cash flow, especially given that the company has wound down its R&D function and lacks a diversified pipeline to offset commercial underperformance.
The $100 million TRELEGY milestone payment, frequently cited as a near-term catalyst, is contingent on GSK achieving specific global net sales thresholds for TRELEGY, which grew only 2% year-over-year in Q1 2026 to $873 million, suggesting that the milestone may be delayed or even unattainable if TRELEGY sales growth continues to decelerate, and the company's forward-looking cash flow projections explicitly exclude this potential income, indicating that management itself views it as uncertain rather than a guaranteed near-term driver.
Despite the organizational restructuring reducing headcount by approximately 50% and targeting $70 million in annual cost savings, the company still reported a GAAP net loss of $4.9 million in Q1 2026 and non-GAAP net income of only $0.6 million, revealing that even after significant cost cuts, profitability remains fragile and highly sensitive to fluctuations in YUPELRI sales or unexpected expenses, with the path to sustained GAAP profitability unclear given the permanent loss of R&D capabilities and the structural shift to a pure-play commercial entity.
The ongoing Strategic Review Committee process, while highlighting potential value-maximizing alternatives including a sale, carries substantial execution risk and uncertainty, as there can be no assurance that any transaction will occur, and the company's history of failed pipeline investments (ampspreloxetine) combined with its limited commercial scale raises doubts about its attractiveness as a standalone acquisition target, particularly when compared to larger pharmaceutical companies with diversified respiratory portfolios that could develop internal YUPELRI equivalents or negotiate better terms with Viatris.
YUPELRI's long-term prospects face headwinds from evolving COPD treatment guidelines that increasingly favor triple therapy regimens like TRELEGY over monotherapy LAMAs, potential pressure from future generic entrants despite patent protection through 2039 (which may be challenged via patent evergreening or formulation workarounds), and the inherent limitations of nebulized delivery systems in a market shifting toward inhaler-based therapies, all of which could constrain YUPELRI's market share growth and undermine the durability of its cash flow stream that the bullish thesis depends upon.